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The nevoid basal cell carcinoma syndrome is an auto­
somal dominant disorder that predisposes to basal cell 
carcinomas of the skin, ovarian fibromas, and medul­
loblastomas. Unlike other hereditary disorders asso­
ciated with cancer, it features widespread develop­
mental defects. Laboratory studies of radiation 
sensitivity and chromosome instability over the past 20 
years have generally yielded negative or inconclusive 
results. Recently, screening for allelic loss in sporadic 
and hereditary basal cell carcinomas, hereditary ovar­
ian fibromas, and sporadic medulloblastomas pro­
vided evidence for a tumor suppressor gene on chro-
T he nevoid basal cell carcinoma syndrome (NBCC). also known as Gorlin syndrome and the basal cell nevus syndrome. is an autosomal dominant disorder that predisposes to basal cell carcinomas (BCCs) of the skin, medulloblastomas, and ovarian fibromas. Its 
prevalence has been estimated at 1 per 56,000, and 1- 2% of medul­
loblastomas [1] and 0.5% of basal cell carcinomas are attributable to 
the syndrome [2]. Other neoplasms that probably occur to excess 
include fibrosarcomas, meningiomas, rhabdomyosarcomas, and 
cardiac fibromas. 
In addition to benign and malignant tumors, malformations are a 
striking component. The syndrome is associated with pits of the 
palms and soles, keratocysts of the jaw and other dental malforma­
tions, cleft palate, characteristic coarse facies, strabismus, dysgenesis 
of the corpus callosum, calcification of the falx cerebri, spina bifida 
occulta and other spine anomalies, bifid ribs and other rib anomalies. 
ectopic calcification, mesenteric cysts [3], macrocephaly, and gener­
alized overgrowth [4]. The latter feature has been overlooked in 
many previous reviews in spite of its prevalence. Although not all 
patients with this syndrome are tall, the stature of affected individu­
als is usually greater than that of sex-matched siblings. Some pa­
tients may reach gigantic proportions and many exhibit features 
reminiscent of acromegaly, but detailed endocrinologic studies have 
failed to reveal any abnormalities of growth hormone secretion or 
insulin-like growth factors. 
GENETICS 
As would be expected for a non-lethal, autosomal dominant dis­
order, a positive family history can be elicited from the majority of 
patients; and males and females are affected equally. On careful 
examination nearly one half of first degree relatives of affected 
individuals show signs of the syndrome, and there are very few cases, 
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mosome 9q, important in all three tumor types. Dem­
onstration of a chromosome 9q deletion in an unusual 
patient with this syndrome and genetic linkage studies 
in large kindreds indicated that the nevoid basal cell 
carcinoma syndrome gene maps to the exact same lo­
cation lost in tumors. These data show that tumors arise 
with homozygous inactivation of the gene and imply 
that it normally functions as a tumor suppressor. In 
contrast, hemizygous germ-line mutations lead to 
multiple congenital anomalies. Key words: gorUn $)In­
drome/tumor suppressor/birth defects/neoplasia. J Invest 
Dermatol 103:1265-1305,1994 
of non-penetrance (i.e., the trait being passed from a grandparent to 
grandchild without signs of disease in the intervening generation). 
The extent of expression of the many features of the syndrome is 
variable, but the severity tends to breed true within families [5]. 
There are occasional sporadic cases for which neither parent has any 
features of the syndrome. Such patients could represent non-genetic 
phenocopies, but presumably they result from new mutations in 
germ cells. Individuals affected unilaterally [6] are very likely the 
product of a somatic mutation in one cell of a two-cell embryo. 
THE NATURE OF THE UNDERLYING 
MOLECULAR DEFECT 
Since the syndrome was delineated in the late 1950s and 1960s [7,8], 
numerous laboratory investigations have been undertaken to iden­
tify the underlying molecular basis. The prominence of devel­
opmental defects makes this syndrome unique among autosomal 
dominant disorders predisposing to cancer. The mechanism of car­
cinogenesis has been defined for several other genetic conditions. 
but the clinical features of NBCC do not conform to any known 
class of cancer predisposition syndromes. 
DNA repair defects such as ataxia telangiectasia lead to an excess 
of neoplasia because of an increased rate of genetic alterations [9]. 
Most of these disorders are autosomal recessive, and in vitro studies 
demonstrate decreased cellular survival or chromosome breakage on 
exposure to DNA damaging agents. The disorder in this class most 
similar to NBCC is xeroderma pigmentosum in which there is 
increased risk of skin cancer due to failure in repairing sunlight-in­
duced DNA damage. However, in contrast to NBCC, XP is charac­
terized by excessive sun burning, freckling, premature aging of the 
skin, and predisposition to squamous cell carcinomas and melano-
.I. mas (Fig 1). In vitro studies with DNA damaging agents in NBCC 
cell lines have failed to produce convincingly positive results. Chro­
mosome instability, as evidenced by fragility [10,11] and increased 
rates of sister chromatid exchange [12-15J, has been implicated. 
However, these findings were refuted by carefully controlled stud­
ies [16,17]. Analyses of cellular radiation sensitivity have yielded 
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Figure 1. XP and NBCC. Top: this 13-year-old girl with XP has had 
more than 10 epidermal malignancies excised (both squamous and basal cell 
carcinomas). Note the severe actinic damage with lentigines and atrophy 
(photograph courtesy of Drs. J. DiGiovanna and G. Peck). Bottom: this 
17-year-old girl with NBCC had 10 basal cell carcinomas removed from 
the periorbital region. but her skin is otherwise normal. 
conflicting results, but in no case was a major deviation from normal 
seen [11,13,18-22]. 
Ecogenetic traits are another type of cancer predisposition syn­
drome [23]. This term describes disorders in which there is an un­
usual susceptibility to an environmental agent. An example is ocu­
locutaneous albinism in which affected individuals living in 
temperate climates may never develop skin cancer whereas the life 
span of those in sunny, equatorial climates is limited by multiple 
skin cancers. No hypersensitivity to a specific environmental car­
cinogen has been identified as the cause of basal cell carcinomas and 
the other tumors in NBCC. 
Two other mechanisms of cancer predisposition are germline 
activation of oncogenes or germline inactivation of tumor suppres­
sor genes. Normal cell regulation results from a balance between the 
function of these two types of genes. When an oncogene is activated 
through overexpression or point mutation to a hyperfunctioning 
form, it exerts a dominant positive effect on cell growth. Recently 
germline activation of an oncogene has been identified as the cause 
of multiple endocrine neoplasia type two [24]. In spite of exhaustive 
searches for oncogene mutations in cancer predisposition syn­
dromes over the past 10 years, no other disorders of this type have 
been identified. 
Mutations in tumor suppressor genes appear to be responsible for 
the vast majority of autosomal dominant cancer predisposition syn­
dromes. Like all genes in the human body (except those on the X 
and Y chromosomes), there are two copies of each tumor suppressor 
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gene in every normal cell. Mutational inactivation of one copy of a 
tumor suppressor typically has very little effect because the second 
copy is sufficient to keep the cell under control. Loss of function of 
both copies has a powerful growth-promoting effect [25]. Usually 
inactivation of a tumor suppressor is a somatic event that occurs by 
random chance during DNA synthesis or as the result of exposure to 
environmental carcinogens, but rare individuals are born with heri­
table, germline mutations of tumor suppressors. Germ-line muta­
tion of one homologue of a tumor suppressor can cause an autoso­
mal dominant syndrome of cancer predisposition because the 
remaining homologue is likely to be lost in a proportion of suscepti­
ble cells through somatic events [26]. Additional phenotypic effects 
of constitutional mutations are not typically seen in these syn­
dromes because loss of just one copy has little effect on cell function. 
The behavior of neoplasms in NBCC suggests that the underly­
ing defect in this disorder may be mutation in a tumor suppressor 
gene. Like the malignancies arising in hereditary retinoblastoma in 
which the RB1 tumor suppressor gene is mutated [27] and Li-Frau­
meni syndrome involving germ-line mutation of the P53 tumor 
suppressor [28], BCCs in this disorder are multiple, occur relatively 
early compared with sporadic tumors of the same type, and tend to 
develop after exposure to ionizing radiation with a very brief la­
tency period [29]. If the NBCC gene functions as a tumor suppres­
sor then it should be inactivated in BCCs. Inactivation of a tumor 
suppressor gene frequently occurs through point mutation of one 
homologue and loss of the other homologue by nondisjunction, 
deletion, or mitotic recombination. The latter mechanisms result in 
loss of heterozygosity for polymorphisms in the chromosomal re­
gion surrounding the tumor suppressor gene [30]. 
GENETIC ANALYSIS OF TUMORS ASSOCIATED 
WITH NBCC 
Attempts at genetic analysis ofBCCs have been hampered by sev­
eral tumor characteristics [31]. BCCs are often small at the time of 
diagnosis and routine surgical specimens contain a large amount of 
surrounding normal tissue. Genetic alterations in tumor cell DNA, 
particularly allelic loss, can be masked by the presence of DNA from 
admixed normal tissue. Pure tumor DNA could be obtained from 
cultured cells, but BCCs are slow-growing neoplasms and are ex­
tremely difficult to establish in culture. Microscopically controlled 
surgery is a procedure used to remove large skin tumors in which the 
central tumor mass is debulked and the margins are excised under 
microscopic direction [32]. The debulked material contains homo­
geneous tumor relatively free of surrounding normal stroma. 
In an initial study of matched blood and tumor samples from 18 
patients undergoing microscopically controlled surgery, 16 with 
sporadic tumors and two with NBCC, restriction fragment length 
polymorphism, analysis of 33 loci from 22 autosomes showed chro­
mosome 9 to be the only site with frequent allelic loss [33]. Com­
bining results of the two markers tested on chromosome 9, D9S18 
(9p13) and D9S9 (proximal 9q), nearly 50% (seven of 15) of infor­
mative tumors showed allelic loss. Three tumors showed additional 
loss on one other chromosome. One of eight informative tumors 
lost THRB on chromosome 3p, one of seven lost D15S2 on chro­
mosome 15q, and one of 12 lost P53 on chromosome 17p. In later 
studies point mutations were identified in one or both copies of the 
P53 gene in many tumors [34]. 
With additional restriction fragment length polymorphisms and 
short tandem repeat markers on chromosome 9 allelic loss was 
found in 72% of tumors (Fig 2). Four tumors showed loss for all 
informative markers, five retained distal 9q but lost more proximal 
markers, one retained only 9p, and three had interstitial deletions of 
9q allowing localization of allelic loss to the mid portion of 9q. The 
area of overlap included 9q22-q31 for all informative tumors, and 
both hereditary tumors showed allelic loss at this location. 
Studies of hereditary ovarian fibromas [33] and sporadic medullo­
blastomas Gohn W. Bare and Ervin Epstein, unpublished data) indi­
cated that these tumor types can also arise with allelic loss of chro­
mosome 9q. 
128S BALE ET AL 
A B c 
1 2 1 2 1 2 
Figure 2. DNA samples from peripheral blood leukocytes (1) and 
matched basal cell carcinoma tissue (2) were typed for the short 
tandem repeat marker. D9S127. that lies on chromosome 9q31. 
Arrows indicate the alleles lost in tumor samples. Panel A shows loss of the 
smaller allele. panel B shows no allelic loss. and panel C shows l�ss of the 
larger allele. The faint residual bands in panels A and C reflect adrruxture of a 
small amount of normal tissue in the tumor specimens. 
MAPPING THE NBCC GENE 
Two lines of evidence indicated that the NBCC gene maps to ex­
actly the same location that is consistently deleted in tumors. A 
30-year-old woman was identified with typ.
ical NBCC as well as 
congenital heart disease (patent ductus artenosus). �ental r�tar�­
tion, and a benign intestinal tumor. On cytogenetIc exanu�ation 
one copy of chromosome 9 showed a deletion of 9q22-q3 � (F.lg 3). Polymorphism studies of the patient and her two parents mdlcated 
that she failed to inherit a maternal allele for the markers D9S127 
and D9S53, which lie in the 9q22-31 region. Polymorphic markers 
proximal and distal to this region showed a normal segregation 
pattern. These data suggestc;d the possibility that the patient had a 
contiguous gene sy�drome mvolvmg the N�CC gene and several 
others (Mae Gailam al!'d A11e� Bale,. unpublIshed. 
da�). . 
Confirmation of this location relled on genetic hnkage studies 
[33]. Five large kindreds were a�alyzed for polymorphi� mar�ers 
spanning chromosome 9q. Typical features of �BCC mclud�g 
multiple BCCs, palmar pits, and keratocysts of the Jaw were seen m 
all five kindreds. Diagnosis was based on the presence of two of 
these features or one of these features plus a first degree relative with 
the syndrome. There was some degree of inte�a.nnlial clinical �e�­
erogeneity among the five kindreds. Three families had a very Slffil-
! 
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Figure 3. Cytogenetic analysis of peripheral blood lymphocytes in a 
patient with NBCC. congenital heart disease. and a benign intestinal 
neoplasm. One copy of chromosome 9 has a deletion in the long arm. The 
ideogram at right shows the breakpoints on chromosome 9q22 and 9q31-32. 
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Figure 4. Cosegregration of 09S29 with NBCC. RFLP typing was 
performed by Southern blot analysis using 5 Jl.g ofTaql-digested DNA from 
each family member and probe LAMP92. Affected individuals are shown as 
black symbols. Females are represented as circles and males as squares. The 
14-kb allele segregated with the disease gene and the 7.6-kb allele with the 
normal gene in this kindred (figure appeared originally in reference [33J and 
is reprinted by permission of the journal Cell). 
lar phenotype. Skin, dental, and typical facial features were most 
pronounced in these families with some individuals showing char­
acteristic skeletal and brain anomalies. One kindred had a more 
severe phenotype with pronounced skeletal manifestations, and one 
kindred was less severely affected and rarely showed any skeletal 
anomalies. In spite of these phenotypic differences, the disease in all 
of these families cosegregated with markers on chromosome 9q22-
q31 (Fig 4). Similar results were obtained in a large number of 
families of Northern European origin [35,36], American black fam­
ilies. and Ashkenazi Jews [37]. 
THE NBCC GENE AS A TUMOR SUPPRESSOR 
These data support the hypothesis that NBCC is caused by muta­
tion in a tumor suppressor gene on chromosome 9 that plays an 
important role both in normal development and in the growth 
control of the precursor cells for BCCs and other tumors. The 
demonstration of a constitution deletion of one copy of chromo­
some 9q22 - 31 in a patient with the syndrome indicates that inacti­
vation of the gene rather than an overexpression leads to cancer 
predisposition. BCCs and ovarian fibromas from patients with 
NBCC show loss of heterozygosity in the exact region that the gene 
maps by linkage. Presumably the precursor cells contain a hereditary 
first hit and the allelic loss represents loss of the normal allele. 
Sporadic BCCs may arise from susceptible cells in which two so­
matic hits have occurred, one of which is manifested as allelic loss. 
Inactivation of the NBCC gene in BCCs may be a necessary if not 
sufficient event for carcinogenesis. The majority of neoplasms ana­
lyzed, both sporadic and hereditary, showed allelic loss for chromo­
some 9q22-q31. Because homozygous inactivation of tumor sup­
pressor genes can occur through several mechanisms, not all of 
which result in loss of heterozygosity, it is possible that the relevant 
gene is inactive in all BCCs even though genetic alterations are seen 
in only two thirds of sporadic tumors. Point mutations, which are 
not manifested as allelic loss, are a likely mechanism of inactivation 
i in sporadic cases. The most important risk factor for BCCs in indi­. viduals who are not genetically predisposed is ultraviolet (UV) ex­
posure. UV radiation contributes to carcinogenesis through pro­
duction of C to T transitions in DNA and not by induction of large 
scale chromosome rearrangements [38]. It is likely that in tumors 
not showing allelic loss, both copies of the gene have undergone 
point mutations. This hypothesis would predict that BCCs related 
to exposure to ionizing radiation, which causes chromosome breaks, 
would more often show allelic loss. Another mechanism by which 
tumor suppressor genes may be inactivated is dominant �ega�ve 
mutation, in which the product of the mutant allele forms mactlve 
complexes with the normal gene product [39]. Inactivation of one 
allele by this mechanism creates the biochemical equivalent of a 
homozygous genetic defect. Mutations of this type would be un-
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likely as the first hit in patients with NBCC because the resulting 
constitutional phenotype reflecting homozygous inactivation of the 
gene would probably be incompatible with life. However, in spo­
radic tumors, there may be a bias toward this type of mutation 
because tumors could arise with only one somatic event. 
The pattern of allelic loss in BCCs suggests that inactivation of 
the relevant gene on chromosome 9 is an early event in tumorigene­
sis. Three tumors with allelic loss on chromosome 9 showed addi­
tional areas of loss on other chromosomes, but no tumors had loss on 
other chromosomes without involvement of chromos9me 9. Stud­
ies of neoplasms in other organs indicate that transformation of cells 
from completely normal to frankly malignant may require mul�ple 
genetic alterations, some of which correlate with altered histolOgic 
appearance and biologic behavior [40]. In the context of multistep 
carcinogenesis BCC is especially interesting because its clinical be­
havior ranges from extremely indolent to very aggressive. In addi­
tion there are several histologic and clinical subtypes with different 
therapeutic and prognostic implications [41]. Future studies will 
address the question of whether the observed allelic loss on chro­
mosomes other than 9 as well as activating mutations of dominant 
oncogenes correlate with more anaplastic histology and more ag­
gressive biologic behavior. 
TUMOR SUPPRESSORS AND 
DEVELOPMENTAL DEFECTS 
Given the clinical features of the syndrome, the gene for this dis­
order must play a role in both normal embryogenesis and continued 
control of cell growth and differentiation. Bone malformations 
(vertebral and rib anomalies), forebrain malformations (dysgenesis 
of the corpus callosum), and facial dysmorphology reflect early 
embryonic effects. The gene appears to function in different tissue 
types in the postnatal period as reflected by abnormalities of skin 
(BCCs, palmar pits), ovary (fibromas), and hindbrain (medulloblas­
toma). 
The finding of developmental defects in a syndrome due to inac­
tivation of a tumor suppressor gene constitutes a paradox because 
inactivation of one copy of a tumor suppressor classically has little or 
no effect on cell function. However, it is possible that some of the 
defects in NBCC can be explained by a two-hit mechanism [42] 
similar to the two-hit mechanism of neoplasia. Like the neoplasms 
in many cancer predisposition syndromes, many of the develop­
mental defects in NBCC are often multiple and bilateral (e.g., spina 
bifida occulta, bifid ribs, and jaw cysts) but isolated defects of the 
same type are seen occasionally in the general population. It is possi­
ble that these developmental defects arise from a second hit in an 
early progenitor cell of the relevant tissue (Fig 5). Ajaw cyst could 
originate from a single embryonic or fetal cell that has suffered a 
second hit and fails to exhibit normal differentiation and growth 
control. Over many years the progeny of this cell develops into a 
clinically evident cyst of the jaw. In a perfect analogy to tumors seen 
in cancer predisposition syndromes, these cysts are often multiple 
and bilateral in patients with NBCC, but they may also occur as 
isolated anomalies in patients who do not have the syndrome. 
A role for tumor suppressors in development is not completely 
unpredcedented. WT1, a tumor suppressor gene that is inactivated 
in Wilm's tumor, may also play a role in normal development. A 
small proportion of germ-line WTl mutations lead to developmen­
tal defects of the urogenital system as well as predisposition to 
Wilm's tumor [43]. The mechanism by which the congenital 
anomalies arise is unknown. 
CONCLUSIONS 
NBCC is an autosomal dominant disorder characterized by cancer 
predisposition and multiple developmental defects. There is no 
convincing evidence that a DNA repair defect is responsible for the 
manifestations of this disorder and no hypersensitivity to any envi­
ronmental agent has been demonstrated. Mapping of the NBCC 
gene to chromosome 9 and the demonstration that the exact same 
region is deleted in a high percentage of basal cell carcinomas and 
other tumors related to the disorder provide strong evidence that the 
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Figure S. Hypothetical two-hit mechanism for developmental de­
fects. Cells in a developing NBCC fetus undergo a second hit and give rise 
to dysregulated clones. These clones lead to focal developmental defects 
such as jaw cysts, bifid ribs, and spina bifida occulta. 
gene functions a tumor suppressor. Inactivation of this gene may be 
a necessary if not sufficient event for the development of BCCs. 
In contrast to other disorders caused by tumor suppressors con­
genital anomalies are a prominent feature of NBCC. One hypothe­
sis to explain at least some of these anomalies is a two-hit mecha­
nism in which a single fetal or embryonic cell that has lost the 
normal copy of the gene gives rise to a developmentally abnormal 
clone. However, other symmetric generalized features of the syn­
drome (e.g., overgrowth, corpus callosum defects) suggest that loss 
of just one copy of the NBCC gene exerts an effect on growth and 
differentiation. 
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